Bharat Biotech's nasal Covid vaccine gets DCGI nod trial for
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Pharma major Bharat Biotech has received approval from India's drug regulator to conduct mid-to late-stage trials of their nasal Covid-19 vaccine candidate, the Union ministry of science said. “This is the first of its kind Covid-19 jab to undergo human clinical trials in India," the ministry said. "

“BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine.BBIL has in-licensed technology from Washington University in St Louis, USA," it added. Early-stage trials of the vaccine candidate, BBV154, has been completed in subjects aged 18 to 60 years. The company has said that the doses of the vaccine administered to healthy volunteers were found to be well tolerated.

“Bharat Biotech’s BBV154 Covid Vaccine is the first intranasal vaccine being developed in the country entering into late-stage clinical trials," said Renu Swarup, chairperson of the Biotechnology Industry Research Assistance Council. The company's Covaxin Covid-19 vaccine was approved for emergency use in the country in January this year. It is being administered through an injection in the country's inoculation drive.

Suchitra Ella, Joint Managing Director, Bharat Biotech, on Thursday, said the Hyderabad-based company has supplied 75 million doses of Covaxin so far and more will be supplied this month. The Bharat Biotech official said that Covaxin has 65% efficacy against the B.1.617.2 delta variant of Covid-19. “Our second site is at Ankleshwar-based manufacturing plant. Sample batches are ready, it'll go to CDL Kasauli this month for quality testing," Ella added.